Simulations Plus to Host Virtual Investor Day Highlighting Strategy for the Next Era of Model-Informed Drug Development
MWN-AI** Summary
Simulations Plus, Inc. (Nasdaq: SLP), renowned for its model-informed and AI-accelerated drug development solutions, has announced plans to host a virtual Investor Day on January 21, 2026. This event aims to provide an in-depth overview of the company’s long-term strategic vision, product roadmap, and financial outlook, along with a Q&A session featuring the executive leadership team.
Shawn O’Connor, CEO of Simulations Plus, emphasized that biopharma companies are evolving their approach to drug development by seeking greater predictability, transparency, and scientific rigor. He stated, "Simulations Plus sits at the intersection of these needs," asserting the company's commitment to assisting clients in navigating the complexities of the drug development process.
During the Investor Day, attendees will gain insights into the company’s integrated, AI-enabled modeling ecosystem that encompasses the entire drug lifecycle—ranging from discovery to commercialization. The agenda will cover key topics including the industry’s accelerating shift towards model-informed drug development (MIDD), updates on the company's unified product and technology strategy, advances in scientific services designed to enhance client workflows, and financial priorities moving forward.
The event will be webcast live, with a replay available afterward for those unable to attend in real-time. Simulations Plus positions itself as a leader in the drug development sphere, offering innovative software and consulting solutions that aim to streamline the pharmaceutical development process.
Investors and analysts looking to stay updated with the shifting landscape of biopharma and gain a deeper understanding of Simulations Plus' strategic initiatives are encouraged to register for this informative session. For more information, potential attendees can visit the company’s official website.
MWN-AI** Analysis
Simulations Plus, Inc. (Nasdaq: SLP), a leader in model-informed drug development, is set to host a virtual Investor Day on January 21, 2026. This event is a significant opportunity for current and potential investors to gain insights into the company’s long-term strategy, especially as it transitions into an increasingly AI-driven environment. With the biopharma landscape rapidly evolving, companies are prioritizing predictability and rigor, positioning Simulations Plus to leverage its integrated software and services strategically.
The growing demand for model-informed drug development (MIDD) underscores a critical inflection point in the industry; as such, Simulations Plus' unified strategy is particularly timely. The company’s focus on enhancing client workflows throughout the drug lifecycle highlights its commitment to innovation. Investors should keep a close eye on advancements shared during the Investor Day, particularly regarding how the company plans to address increasing complexities in drug development, which could drive growth moving forward.
Additionally, the company’s emphasis on AI-enabled solutions not only aligns with current market trends but also helps maintain its competitive edge. Investors should take note of Simulations Plus’ financial priorities and outlook presented during the event, as these will offer clues about its growth trajectory and potential revenue streams.
However, potential investors should remain mindful of the forward-looking statements that come with inherent risks. The pharmaceutical industry can be unpredictable, influenced by regulatory, technological, and economic factors. The effectiveness of Simulations Plus’ strategies will depend on their ability to adapt to these changes.
In summary, Simulations Plus represents a compelling investment opportunity, especially in the context of an evolving biopharma landscape. Investors should engage with the upcoming Investor Day to evaluate the company’s prospects in supporting future drug development innovations.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Driving Growth with Integrated Software, Services, and AI-Enabled Ecosystem
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will host a virtual Investor Day on Wednesday, January 21, 2026.
The event will offer investors and analysts an in-depth look at the Company’s long-term strategy, product roadmap, and financial outlook, as well as a Q&A session with the executive leadership team.
“Biopharma companies are rethinking how they develop medicines—prioritizing greater predictability, transparency, and scientific rigor at every step. Simulations Plus sits at the intersection of these needs,” said Shawn O’Connor, Chief Executive Officer of Simulations Plus. “We are committed to helping our clients navigate this complexity with clarity and confidence. During Investor Day, we will demonstrate how our unified strategy positions us to support the next era of innovation in drug development.”
Attendees will gain insight into Simulations Plus’ vision for an integrated, AI-enabled modeling ecosystem spanning discovery, development, clinical operations, and commercialization. The agenda will include updates on:
- The industry environment and the accelerating adoption of model-informed drug development (MIDD)
- The Company’s unified product and technology strategy
- Advances in scientific services supporting client workflows across the drug lifecycle
- Financial priorities and outlook
The event will be webcast live, and a replay will be posted following the event.
Event Details
- Date: Wednesday, January 21, 2026
- Time: 1:00 PM ET – 2:30 PM ET
- Location: Virtual
- Webcast Registration: Here
About Simulations Plus, Inc.
Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com .
Environmental, Social, and Governance
We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive impact. To learn more about our latest initiatives and priorities, please visit our website .
Forward-Looking Statements
Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will”, “can”, “believe”, “expect,” “anticipate” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. These forward-looking statements are based on current assumptions and expectations that involve risks and uncertainties that could cause the actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our new internal operational structure, our ability to maintain our competitive advantages and commercialize AI and cloud-enabled solutions, evolving regulatory and data privacy standards governing AI technologies, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual and current reports and filed with the U.S. Securities and Exchange Commission.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251218867761/en/
Investor Relations Contact :
Lisa Fortuna
Financial Profiles
310-622-8251
slp@finprofiles.com
FAQ**
How does Simulations Plus Inc. SLP plan to leverage its AI-enabled ecosystem to enhance model-informed drug development during the upcoming Investor Day on January 22026?
What specific advancements in scientific services will Simulations Plus Inc. SLP highlight to support client workflows across the drug lifecycle during this virtual event?
Can you elaborate on the Company's financial priorities and outlook that Simulations Plus Inc. SLP intends to discuss at the Investor Day, particularly in light of current industry trends?
What are the main risks and uncertainties that Simulations Plus Inc. SLP anticipates could impact its strategic goals and financial performance as outlined in their forward-looking statements?
**MWN-AI FAQ is based on asking OpenAI questions about Simulations Plus Inc. (NASDAQ: SLP).
NASDAQ: SLP
SLP Trading
-1.91% G/L:
$12.055 Last:
86,932 Volume:
$12.35 Open:
